UNSPSC 51162038: Indacaterol/Glycopyrronium bromide

Indacaterol/glycopyrronium bromide is a fixed-dose combination medication for inhalation consisting of the following two active ingredients: Indacaterol maleate, an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA); Glycopyrronium bromide (glycopyrrolate), a muscarinic anticholinergic.

UNSPSC 51162038 Indacaterol/Glycopyrronium bromide is a Commodity code for a combination respiratory pharmaceutical product used to treat chronic obstructive pulmonary disease. The recent state and local opportunities tagged to this code do not reflect pharmaceutical procurement for this or any comparable drug product; instead, they span emergency medical services supply distribution, long-term care pharmacy services, forensic laboratory reference standards, opioid-use-disorder treatment infrastructure, and related public-health infrastructure. A single opportunity—a Dane County RFP for pharmaceutical services to Badger Prairie Health Care Center—involves genuine pharmacy operations, but the scope is comprehensive long-term care medication management rather than a specific drug formulary. The code shows minimal recent activity aligned with its nominal scope; the opportunities present reflect either misclassification or incidental mention of pharmaceutical procurement within broader infrastructure or service procurements.

Geographic activity spans Florida (Collier County, Seminole County, Clay County, Palm Bay, Marion County), Wisconsin (Dane County), Oregon (Washington County), Kentucky (Owensboro), Arizona (Tucson), Texas (West Texas Centers, Williamson County), California (San Mateo County), and the District of Columbia. No repeat buyers or concentration emerges. Representative recent opportunities include Dane County's RFP 2026RFP061PR for pharmaceutical services at Badger Prairie Health Care Center (response deadline October 22, 2026), which involves medication dispensing, delivery, and supply-chain integration across a five-year term with annual funding of approximately $125,000; and the City of Tucson Fire Department's RFP 260217 for BLS/ALS pharmaceuticals and supplies with VendNovation vending and software support (response deadline June 24, 2026, federally funded through ARPA, HUD, and FTA with prevailing wage, Davis-Bacon, and Section 3 compliance). A pursuit strategy under this code should confirm code-to-opportunity alignment before investing in proposal effort, as the recent posting mix does not consistently reflect indacaterol/glycopyrronium bromide or comparable respiratory-pharmaceutical procurement.